Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | RARG | P13631 | 10/20 | 0.33 |
| ▸ | RXRA | P19793 | 9/20 | 0.32 |
| ▸ | HNF4A | P41235 | 2/20 | 0.32 |
| ▸ | RARA | P10276 | 6/20 | 0.31 |
| ▸ | RARB | P10826 | 4/20 | 0.31 |
| ▸ | RXRG | P48443 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8560366 | 0.81 | KDM4C (0.39) | KDM4CRARGRXRAHNF4ARARA | |
| SCHEMBL7688528 | 0.80 | RARA (0.34) | KDM4CRARGRXRARARARARB | |
| SCHEMBL6297298 | 0.77 | RXRA (0.46) | RARGRXRARARARARBRXRG | |
| SCHEMBL8558259 | 0.73 | F2 (0.38) | KDM4CRARGRXRARARBRXRG | |
| SCHEMBL8560364 | 0.73 | CYP3A4 (0.38) | KDM4CRARGRXRARARARARB | |
| SCHEMBL6708918 | 0.73 | RARA (0.57) | RARGRARARARB | |
| SCHEMBL6596539 | 0.71 | RARA (0.44) | RARGRARARARBHIF1A | |
| SCHEMBL6292634 | 0.70 | RXRA (0.45) | RARGRXRAHNF4ARARARARB | |
| SCHEMBL6293050 | 0.69 | RARA (0.60) | RARGRXRARARARARBRXRG | |
| SCHEMBL8671861 | 0.69 | RARB (0.58) | RARGRARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855832-B2 | O- or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20030078440-A1 | O- or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078440-A1 | O- or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | RARB, RARA, RXRB | KDM4C 4308/4885RARG 5/4885RXRA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.